Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies

被引：19

作者：

Cilibrasi, Chiara ^{[1
]}

Papanastasopoulos, Panagiotis ^{[1
]}

Samuels, Mark ^{[1
]}

Giamas, Georgios ^{[1
]}

机构：

[1] Univ Sussex, Sch Life Sci, Dept Biochem & Biomed, Brighton BN1 9QG, E Sussex, England

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2021年 / 22卷 / 21期

关键词：

breast cancer; immunoediting; immune tumour microenvironment; immunotherapy; TUMOR-ASSOCIATED MACROPHAGES; REGULATORY T-CELLS; GROWTH-FACTOR-BETA; METASTATIC BREAST; INFILTRATING LYMPHOCYTES; DOUBLE-BLIND; PEMBROLIZUMAB; NEUTROPHILS; CHEMOTHERAPY; MECHANISM;

D O I：

10.3390/ijms222112015

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Over the past 50 years, breast cancer immunotherapy has emerged as an active field of research, generating novel, targeted treatments for the disease. Immunotherapies carry enormous potential to improve survival in breast cancer, particularly for the subtypes carrying the poorest prognoses. Here, we review the mechanisms by which cancer evades immune destruction as well as the history of breast cancer immunotherapies and recent developments, including clinical trials that have shaped the treatment of the disease with a focus on cell therapies, vaccines, checkpoint inhibitors, and oncolytic viruses.

引用

页码：23 / 45

页数：20

共 114 条

[1] Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study [J].

Adams, S. ;

Loi, S. ;

Toppmeyer, D. ;

Cescon, D. W. ;

De Laurentiis, M. ;

Nanda, R. ;

Winer, E. P. ;

Mukai, H. ;

Tamura, K. ;

Armstrong, A. ;

Liu, M. C. ;

Iwata, H. ;

Ryvo, L. ;

Wimberger, P. ;

Rugo, H. S. ;

Tan, A. R. ;

Jia, L. ;

Ding, Y. ;

Karantza, V. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2019, 30 (03) :405-411

[2] Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].

Adams, Sylvia ;

Diamond, Jennifer R. ;

Hamilton, Erika ;

Pohlmann, Paula R. ;

Tolaney, Sara M. ;

Chang, Ching-Wei ;

Zhang, Wei ;

Iizuka, Koho ;

Foster, Paul G. ;

Molinero, Luciana ;

Funke, Roel ;

Powderly, John .

JAMA ONCOLOGY, 2019, 5 (03) :334-342

[3] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[4] Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses [J].

Anfray, Clement ;

Ummarino, Aldo ;

Torres Andon, Fernando ;

Allavena, Paola .

CELLS, 2020, 9 (01)

[5] Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis [J].

Ardi, Veronica C. ;

Kupriyanova, Tatyana A. ;

Deryugina, Elena I. ;

Quigley, James P. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (51) :20262-20267

[6] Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses [J].

Avigan, D ;

Vasir, B ;

Gong, JL ;

Borges, V ;

Wu, ZK ;

Uhl, L ;

Atkins, M ;

Mier, J ;

McDermott, D ;

Smith, T ;

Giallambardo, N ;

Stone, C ;

Schadt, K ;

Dolgoff, J ;

Tetreault, JC ;

Villarroel, M ;

Kufe, D .

CLINICAL CANCER RESEARCH, 2004, 10 (14) :4699-4708

[7] The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer [J].

Barriga, Vanessa ;

Kuol, Nyanbol ;

Nurgali, Kulmira ;

Apostolopoulos, Vasso .

CANCERS, 2019, 11 (08)

[8] Prognostic value of the Fas/Fas ligand system in breast cancer [J].

Bebenek, Marek ;

Dus, Danuta ;

Kozlak, Joanna .

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2013, 17 (02) :120-122

[9] Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer [J].

Bergenfelz, Caroline ;

Roxa, Anna ;

Mehmeti, Meliha ;

Leandersson, Karin ;

Larsson, Anna-Maria .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (03) :435-448

[10] Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial [J].

Bernal-Estevez, David A. ;

Ortiz Barbosa, Mauren A. ;

Ortiz-Montero, Paola ;

Cifuentes, Claudia ;

Sanchez, Ramiro ;

Parra-Lopez, Carlos A. .

FRONTIERS IN IMMUNOLOGY, 2021, 12

← 1 2 3 4 5 6 7 8 9 10 →